


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61F 2/06</b>		A1	(11) International Publication Number: <b>WO 99/44543</b> (43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: PCT/US99/04686 (22) International Filing Date: 3 March 1999 (03.03.99)		(81) Designated States: CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published <i>With international search report.</i>	
(30) Priority Data: 09/036,665 4 March 1998 (04.03.98) US			
(71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US]; One SCIMED Place, Maple Grove, MN 55311-1565 (US).			
(72) Inventors: LEY, Timothy, J.; 668 Highway 96 West, Shoreview, MN 55126-1905 (US). KVEEN, Graig, L.; 14125 74th Place North, Maple Grove, MN 55311 (US). DORAN, Burns, P.; 11421 80th Street N.E., Albertville, MN 55301 (US).			
(74) Agents: GRAD, Jonathan et al.; Vidas, Arrett & Steinkraus, Suite 2000, 6109 Blue Circle Drive, Minnetonka, MN 55343-9131 (US).			
(54) Title: IMPROVED STENT CELL CONFIGURATIONS			
			
(57) Abstract			
A generally cylindrical, radially expandable stent may be composed of a plurality of interconnected multibonate cell structures. The cells have three or more enlarged end portions radiating from a common center within the cell. The cells may be of tribonate or higher order multibonate configuration. Stents composed up of a series of generally multibonate cell elements are also disclosed.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## IMPROVED STENT CELL CONFIGURATIONS

### Background of the Invention

This application is a continuation-in-part of US Application No. 5 09/036665 filed March 4, 1998, the contents of which is incorporated herein in its entirety by reference.

### Field of the Invention

This invention relates to stents of improved cell configuration.

10

### Brief Description of the Prior Art

Stents are radially expandable endoprostheses which are typically intravascular implants capable of being implanted transluminally and enlarged radially after being introduced percutaneously. They have also been implanted in urinary tracts 15 and bile ducts. They are used to reinforce body vessels and to prevent restenosis following angioplasty in the vascular system. They may be self-expanding or expanded by an internal radial force, such as when mounted on a balloon.

In the past, stents have been generally tubular but have been composed of many cell configurations and have been made of many materials, including metals and 20 plastic. Ordinary metals such as stainless steel have been used as have shape memory metals such as Nitinol and the like. Stents have also been made of biodegradable plastic materials. Such stents have been formed from wire, tube stock, and the like.

### Summary of the Invention

25 This invention provides new configurations of the cells making up stents which may be adapted to all of the various types of prior art stents described above and/or known previously in the art. In general, as will be seen from the embodiments described hereinafter, the improved cell configurations are generally trichotomous, i.e., divided into three parts. More particularly, the cells are of a triskelion-like or trifurcate 30 configuration, i.e., composed of three parts with axes of each part radiating from a common center. There are numerous advantages to the new configurations. For example, the configurations of the invention limit recoil and add resistance to

compression for an expanded stent and provides increased side branch access, among other things. Also, the stents of this invention are longitudinally flexible.

The invention is also directed to a stent of generally cylindrical shape composed of at least one multibonate cell structure and desirably of a plurality of 5 interconnected multibonate cell structures, as defined below. The multibonate structures may be interlocking and may be regularly arranged.

The invention contemplates stents having only one type of multibonate cell structure present as well as stents having a plurality of different multibonate cell structures present. Stents comprised of a plurality of multibonate cell structures of 10 different order are also contemplated.

The invention is also directed to a stent comprised of a plurality of interlocking cell structures selected from the group consisting of bonate cell structures oriented at an oblique angle relative to the longitudinal axis of the stent, multibonate cell structures and combinations thereof.

15

#### Brief Description of the Figures

Figure 1 is a flat plan view of an embodiment of a stent configuration of the invention in the unexpanded condition in which the cells share common elements;

Figure 2 is an end view of a tubular stent of Figure 1 according to the 20 invention in its normal unexpanded condition;

Figure 3 is a detail view of a portion of Figure 1, as indicated;

Figure 4 is a view of the stent of Figures 1 and 2 showing the expanded condition;

Figure 5 is another embodiment of the invention, similar in view to that 25 of Figure 1, showing the flat plan of the stent in the unexpanded condition;

Figure 6 is a detail view of a portion of Figure 5, as indicated;

Figure 7 is a flat plan view of another cell configuration according to the invention;

Figure 8 is a schematic showing of yet another cell configuration;

30 Figure 9 is a flat plan view showing a form of interconnection between cells;

Figure 10 is a flat plan view showing another form of interconnection between cells;

Figure 11 is a flat plan view showing yet another embodiment of the invention;

Figure 12 is a flat plan view showing a bonate cell structure;

5 Figure 13 is a flat plan view showing a multibonate (tribonate) cell structure;

Figure 14a is a flat plan view showing yet another tribonate embodiment of the invention;

Figure 14b is a flat plan view showing the rotational axis of symmetry of the multibonate cells of Fig. 14a;

10 Figure 14c is a flat plan view showing the planes of reflectional symmetry of the multibonate cells of Fig. 14a;

Figure 15a is a flat plan view showing yet another tribonate embodiment of the invention;

15 Figure 15b is a flat plan view showing the plane of reflectional symmetry of the multibonate cells of Fig. 15b;

Figure 16a is a flat plan view showing yet another tribonate embodiment of the invention;

Figure 16b is a side elevational view of the stent of Fig. 16a;

Figure 16c is a three dimensional isometric view of the stent of Fig. 16a;

20 Figure 16d is a magnified view of an end portion of the stent as shown in Fig. 16d;

Figure 16e is a three dimensional isometric view of a stent similar to that of Fig. 16c, but shorter;

25 Figure 17 is a flat plan view showing yet another embodiment of the invention which includes tribonate and bonate structures;

Figure 18 is a flat plan view showing yet another embodiment of the invention which includes tribonate and bonate structures;

Figure 19 is a flat plan view showing a quadribonate embodiment of the invention;

30 Figure 20a is a flat plan view showing yet another quadribonate embodiment of the invention;

Figure 20b is an enlarged portion of Fig. 20a showing the various planes of symmetry;

Figure 21a is a flat plan view showing yet another tribonate embodiment of the invention;

Figure 21b is an enlarged portion of Fig. 21a showing the various planes of symmetry;

5 Figure 22a is a flat plan view showing yet an embodiment of the invention which includes tribonate and quadribonate cells;

Figure 22b is an enlarged portion of Fig. 22a; and

Figure 23 is a flat plan view showing an embodiment of the invention including obliquely oriented bonate cells.

10

Detailed Description

An embodiment of a generally cylindrical stent 10 according to the invention is illustrated in Figures 1-4. It comprises a metal tube as shown in the Figure 2 end view, such as Nitinol, or stainless steel preferably, which has been etched or more preferably laser cut to the configuration shown in the flat plan view of Figure 1. The configuration may be formed in flat sheet, rolled into a cylinder and welded or the like, or the configuration may be formed directly from a small tube such as a hypotube. An enlarged detail of Figure 1 is shown in Figure 3. This configuration is made up of a series of generally triangular-like expansion cell elements generally indicated at 11 (see 15 darkened cell in the Figures for clarity) having relatively straight segments 13, 15 and 17, relatively straight segments 12, 14 and 16 and curvilinear segments 18-23. Segments 12, 14 and 16 comprise a first set of three segments arranged relative to each other in triangular spaced positions as shown in Figure 3. Segments 13, 15 and 17 are placed in triangular spaced positions also but are outwardly positioned with respect to 20 segments 12, 14 and 16 and are placed opposite paired ends of 12/16, 16/14 and 12/14 as shown. In this embodiment these segments 12-17 are all straight. Curvilinear segments 18, 19, 20, 21, 22 and 23 interconnect segments 12/13, 13/16, 16/17, 14/17, 14/15 and 12/15 as shown. Preferably the segments are curvilinear, more preferably they are S-shaped as shown, although they can be made up of one or 25 more straight sections. The resultant cell exhibits the triskelion configuration, having the three part axis 25 radiating from a common center. Cells 11 in this embodiment are arranged in an internested arrangement or network as shown in the Figures with adjacent 30 cells sharing common sides or segments.

Finally, the longitudinal axis of the stent is indicated by reference numeral 270 in the above figures and in all of the remaining figures of the application.

When the stent of Figures 1 and 2 is expanded, as shown in Figure 4, on a balloon for example (not shown), the cells 11 take on a new configuration as shown,

- 5 the segments making up the stent being indicated by the same numbers as used in Figures 1 and 3.

Referring now to Figures 5-6, another internested stent embodiment is shown. In this embodiment, as seen in Figures 5 and 6, expansion cells 11, best seen in the detail of Figure 6 (again a cell is indicated by darkening) are shaped the same as 10 cells 11 in Figures 1-3. However, they are skewed with respect to the longitudinal axis 270 of the stent rather than being arranged in parallel longitudinal lines in which the cells are positioned perpendicular to the longitudinal axis of the stent as in Figures 1-4.

- 15 Referring now to Figure 7, another cell configuration is shown to demonstrate that elements or segments 12, 14 and 16 need not be straight but may be arcuate as shown, either inwardly as shown in the Figure or outwardly.

The cell configuration shown in Figure 8 is a three-lobed configuration preferably used in an interconnected cellular arrangement with individual connecting members as discussed in Figures 9 and 10. In this embodiment three sections, 12a/12bm 14a/14bm and 16a/16b, radiate from a common center to terminate in 20 enlarged end portions 13, 15 and 17, respectively. However, Figures 9 and 10 make use of cell configurations similar to those shown in Figures 1-6.

- In Figure 9, a series of sets of cells, each set consisting of six cells 11 arranged in a circular pattern 28, repeated throughout the stent body. Each cell 11 is connected to three adjacent cells 11 by three connector segments 30 in a repeating 25 pattern through the stent body. In this particular arrangement, the connector members 30 extend from an inner segment on one cell to an inner segment on an adjacent cell, as shown. The connector members may be straight or curved and may be in various shapes such as zig-zag or S-shaped, etc.

- 30 In Figure 10 the connector members 30 extend from an inner segment on one cell to an outer segment on the adjacent cell as shown. Cells 11 are arranged in vertical rows in this embodiment but are staggered longitudinally as can be seen in the Figures.

Figure 11 is illustrative of an internested stent configuration in which all segments of each cell are straight as opposed to curvilinear.

For the purposes of this disclosure, the term 'bonate' refers to a structure which has relatively wide end portions joined by a connecting portion which is, at least 5 in part, relatively narrow. A bonate cell structure is illustrated generally at 100 in Fig. 12. Bonate cell structure 100 has a first relatively wide end portion 104 of the cell and a second relatively wide end portion 108 of the cell and a relatively narrow connecting portion 112 of the cell and resembles a dog bone. Connecting portion 112 may also be relatively narrow in only a portion thereof. Stents having bonate cell structures have 10 been disclosed in commonly assigned US application 08/947620 filed October 9, 1997, the contents of which are incorporated herein in their entirety by reference.

The term 'multibonate', for the purposes of this disclosure, refers to a structure which has three or more relatively wide end portions each of which is joined to a common portion via a relatively narrow connecting portion. Further, each of the end 15 portions radiates from at least one common point in the common portion, desirably in the center of the common portion. The relatively wide end portions of a multibonate structure may be lobe shaped. Also desirably, each of the end portions emanates from a vertex region of the common portion. One such multibonate cell structure is shown generally at 120 in Fig. 13. Multibonate structure 120 consists of three relatively wide 20 end portions 124 of the cell each of which is joined to a common portion 128 of the cell via relatively narrow connecting portions 132 of the cell. It is noted that each of end portions 124 extends from a common point 129. It is also noted that each of end portions 124 extends from a vertex 131 of common portion 128. The multibonate structure of Fig. 13 is also termed a tribonate structure because of the presence of the 25 three end portions. Multibonate structures with four relatively wide end portions would similarly be termed 'quadribonate' and multibonate structures with five, six, seven and eight relatively wide end portions would be termed 'pentibonate', 'hexibonate', 'heptabonate' and 'octabonate', respectively. A multibonate structure with 'n' end portions is referred to as an 'n<sup>th</sup> order' multibonate structure.

30 The present invention is directed generally to stents formed of multibonate cell structures. In one embodiment, the invention is directed to a stent of generally cylindrical shape comprised of at least one multibonate cell structure and desirably of a plurality of interconnected multibonate cell structures. The multibonate

cell structures may optionally be regularly arranged. One such stent is shown in the flat in Fig. 14a. Stent 200 consists of a plurality of interconnected tribonate cell structures 120. Tribonate cell structures are arranged in interconnected longitudinal rows 204. Tribonate cell structures within a row are seen to be tessellated or interlocking with adjacent cell structures having at least one member 124a in common. Member 124 simultaneously serves as an end portion of a cell structure and as a portion of the central portion of a cell structure. Tribonate cell structures 120 in adjacent rows 204 are also seen to share a member 124b in common. Member 124b, similarly, serves as an end portion in one cell structure and as a portion of the central portion of a cell in an adjacent row. All of the tribonate structures 120 in adjacent rows 204 of multibonate structures are identically oriented relative to the longitudinal axis of the stent.

It is further noted that tribonate cells 120 of Fig. 14a have a common portion 128 which is substantially triangular and moreover formed substantially in an equilateral triangle. Each tribonate cell 120 has a threefold rotational axis of symmetry (C<sub>3</sub> axis of symmetry) 121 in the flat, through the center of the cell, as shown in Fig. 14b. Each tribonate structure further is characterized by three planes of reflectional symmetry ( $\sigma_v$ ) 123a-c, as shown in Fig. 14c. To that end, first, second and third end portions 124a-c, respectively, are the same shape. Moreover, all three connecting portions 132a-c are substantially the same shape, width and length.

The invention further contemplates variations on the multibonate structure in general and the tribonate structure in particular. One such variation is shown in stent 200 in Fig. 15a. Tribonate cell structure 120 is not seen to possess the threefold rotational symmetry of the tribonate cell structure of Fig. 14a. Moreover, cells 120 are seen to possess only a single plane of reflectional symmetry ( $\sigma_v$ ) 123, as shown in Fig. 15b. The cell structure is also seen to vary in that second and third end portions 124b,c are a reflection of one another while end portion 124a differs in shape. End portion 124a is substantially triangular in shape. Its boundaries are defined by two convex side portions 136a,b. End portions 124b,c are each seen to be mushroom shaped. Each of end portions 124a-c extend from connecting portions 132a-c, respectively, which in turn, extend from common portion 128. End portions 124a-c are seen to be mushroom shaped.

Another embodiment of the invention is shown generally at 200 in Figs. 16a-e. As in Fig. 15, tribonate cell structure 120 does not possess the threefold

- rotational symmetry of the tribonate cell structure of Fig. 13. Moreover, cells 120 are seen to possess only a single plane of reflectional symmetry ( $\sigma_v$ ). The cell structure is also seen to vary in that second and third end portions 124b,c are a reflection of one another while end portion 124a differs in shape. End portion 124a is substantially 5 triangular in shape. Its boundaries are defined by two substantially straight side portions 136a,b. End portions 124b,c are each slot shaped.

In another embodiment, the invention is directed to a stent, as shown generally at 200 in Fig. 17. Stent 200 is composed of a plurality of connected tribonate cell structures 120 arranged in longitudinal rows 204. The stent further comprises a 10 plurality of bonate cell structures 140 arranged in longitudinal rows 208 and extending between adjacent rows 204 of tribonate cells 120. Bonate cell structures 140 serve as connectors between adjacent rows of multibonate cells. Bonate cell structures 140 are disposed at an oblique angle relative to the longitudinal axis of the stent. Adjacent rows of bonate cell structures 140 are disposed at equal but opposite angles relative to the 15 longitudinal axis 270 of the stent 200. Bonate cell structures 140 and multibonate cell structures 120 are seen to interlock with one another. End portions 104 of bonate structures 140 form a portion of the side of common portion 128 of tribonate cell structures 120. Similarly, end portions 124b,c of tribonate cell structures 120 form a portion of narrow connecting portion 112 of bonate cell structures 140. Within a 20 longitudinal row 204 of tribonate structures, adjacent tribonate cell structures interlock as well with end portion 124a of a cell forming a part of common portion 128 of an adjacent cell.

The stent of Fig. 17 also differs from the previously shown stents in that tribonate cell structures in adjacent row 204 of tribonate cell structures are oppositely 25 oriented - the cell structures in adjacent rows are rotated by 180° relative to one another. For example, end portions 124a of cell structures in row 204a is directed in an opposite direction relative to end portions 124a of cell structures in row 204b.

Another embodiment of the stent is shown generally at 200 in Fig. 18. Stent 200 is formed of a plurality of multibonate (tribonate) cells 120 and bonate cells 30 140. The stent of Fig. 18 is similar to that of Fig. 17 differing in the shape of end portions 124a. End portion 124a is substantially triangular.

In the embodiments of Figs. 14 and 17, tribonate cell structures include an end portion 124a which is oriented perpendicular to the longitudinal axis of the stent.

The invention also contemplates stents in which multibonate cells include an end portion which is parallel to the longitudinal axis of the stent. Such a stent is shown generally at 10 in Fig. 1. End portions 124b are aligned parallel to the longitudinal axis 270 of the stent.

5 Yet another embodiment of the invention is shown generally at 200 in Fig. 19. Stent 200 is comprised of a series of interconnected, internested quadribonate cells 120 including first quadribonate cells 120a and second quadribonate cells 120b. First and second quadribonate cell 120a,b are differently shaped. End portions 124a of first quadribonate cells 120a also serve as side portions of adjacent second quadribonate 10 cells 120b. First quadribonate cells 120a are joined together by connecting members 154 which also serve as end portions 124b for quadribonate cells 120b. End portions 124a of first quadribonate cell structures 120a are oriented at oblique angles relative to longitudinal axis 270. End portions 124b of second quadribonate cell structures 120b are oriented parallel or perpendicular to longitudinal axis 270 of stent 200. The stent of 15 Fig. 19 is an example of a multibonate stent which consists of at least two different types of multibonate cells of the same order.

Another quadribonate stent is shown generally at 200 in Fig. 20a. Stent 200 is formed of a series of interconnected, internested quadribonate cells 120 including first quadribonate 120a and second quadribonate cells 120b. End portions 124a of first 20 quadribonate cell structures 120a are oriented at oblique angles relative to longitudinal axis 270. End portions 124b of second quadribonate cell structures 120b are oriented parallel or perpendicular to longitudinal axis 270 of stent 200. Stent 200 further includes bonate cell structures 140 oriented at oblique angles relative to the longitudinal axis 270 of the stent. The stent of Fig. 20a is an example of a multibonate stent which 25 consists of at least two different types of multibonate cells of the same order and further contains bonate cells.

The quadribonate cells of Figs. 19 and 20 have a four-fold axis of rotational symmetry. Fig. 20b shows this axis 121 for one quadribonate cell 120b of Fig. 20a. The quadribonate cells also are characterized by four planes of reflectional 30 symmetry 123a-d.

The invention is also directed to a stent, shown generally at 200 in Fig. 21a, which includes elongated tribonate cell structures 120 as well as a row of bonate cell structures 140 at one end of the stent. Tribonate cells 120 include a relatively long,

but relatively narrow connecting portion 132a and relatively short and relatively narrow connecting portions 132b. Tribonate cells 120 have a plane of reflectional symmetry 123a as shown in Fig. 21b.

- Another embodiment of the inventive stent is shown generally at 200 in
- 5 Fig. 22a. The pattern of Fig. 22a is magnified in Fig. 22b. Stent 200 is formed of interconnected tribonate cells 120a and interconnected quadribonate cells 120b. Tribonate cells 120a are formed of three relatively wide end portions 124a, each of which is joined to a common portion 128a of the cell via relatively narrow connecting portions 132a. Quadribonate cells 120b are formed of a four relatively wide end
- 10 portions 124b each of which is joined to a common portion 128b of the cell via relatively narrow connecting portions 132b.

The stent of Fig. 22a also consists of a plurality of interconnected five member spirals 160a, four member spirals 160b and three member spirals 160c. Five member spirals 160a each have five members 163a spiraling about a center portion 165a, four member spirals 160b each have four members 163b spiraling about a center portion 165b and three member spirals 160c each have three members 163c spiraling about a center portion 165c.

Stents having spiral members have also been disclosed in copending, commonly assigned US application 08/846164, filed April 25, 1997 and incorporated

20 herein in its entirety by reference.

More generally, the invention is directed to stents having multibonate cell structures which include at least one end portion disposed parallel to the longitudinal axis of the stent as well as multibonate cell structures which include at least one end portion disposed perpendicular to the longitudinal axis of the stent.

25 The invention further contemplates stents which comprise multibonate cell structure in which none of the end portions are perpendicular or parallel to the longitudinal axis of the stent. Such a stent is shown generally at 200 in Fig. 22a. Each of end portions 124a-c are obliquely oriented relative to the longitudinal axis of the stent.

30 The invention is also directed more generally to stents comprising any order of multibonate structure. A stent comprising sixth order multibonate cell structures is shown generally at 10 in Fig. 9. Hexabonate cell structure 150 consists of six end portions 154 emanating from connector portions 162 which in turn emanate

from a common portion 166. The invention contemplates stents in which adjacent multibonate structures have at least one side in common, as shown in Fig. 9, as well as stent in which adjacent multibonate structures do not have at least one side in common.

The invention is also directed to stents comprising at least one  
5 multibonate structure of  $n^{\text{th}}$  order and at least one bonate structure or multibonate structure of  $m^{\text{th}}$  order where  $n$  and  $m$  are integers,  $n$  and  $m$  are greater than 2 and  $n \neq m$ . These stents comprise at least one multibonate structure of a desired order and one bonate structure or multibonate structure of a different order.

The stent of Fig. 9 comprises sixth order multibonate structures  
10 (hexabonate) 150 as well as third order (tribonate) structures 120. The different order multibonate structures may be interlocking, having parts in common. Tribonate structures 120 in Fig. 9 are interconnected by connecting segments 154 which also serve as end portions of hexabonate cell structures 150. The different order multibonate structures may also be separate from one another and interconnected via connecting  
15 members.

The invention also contemplates stents formed of at least two different types of multibonate cell structures of the same order. For example, the two different types of multibonate cells may have different dimensions or different shapes. This is illustrated in Fig. 10. The stent, shown in the flat, includes first tribonate cells 120a and  
20 second tribonate cells 120b. The shape of first tribonate cells 120a differs from that of second tribonate cells 120b. Figure 19 similarly includes two different types of quadribonate cells 120a,b.

The invention is also directed to a stent comprised of at least one cell structure selected from the group consisting of bonate cell structures oriented at an  
25 oblique angle relative to the longitudinal axis of the stent, multibonate cell structures and combinations thereof. Desirably, the stent will be composed comprised of a plurality of cell structures selected from the group consisting of bonate cell structures oriented at an oblique angle relative to the longitudinal axis of the stent, multibonate cell structures and combinations thereof. Optionally, the cell structures will be interlocking.

30 The invention is further directed to a stent comprising one or more bonate structures oriented at an oblique angle relative to the longitudinal axis of the stent. As shown in the flat in Fig. 23, stent 200 consists of interconnected bonate cell structures 140. The stent includes first bonate cell structures 140a which are oriented at

a first oblique angle relative to the longitudinal axis of the stent 270 and second bonate cell structures 140b which are oriented at a second oblique angle relative to the longitudinal axis of the stent.

- The second oblique angle is equal but opposite to the first oblique angle. The stent of  
5 Fig. 23 consists of alternating rows 280a and 280b of first bonate cell structures 140a and second bonate cell structures 140b, respectively, disposed about the circumference of the stent.

- All of the configurations shown in the Figures may be utilized uniformly throughout a stent or they may be mixed as a means of tailoring a variety of different  
10 characteristics throughout various regions of a stent. Other cell configurations may also be used in the practice of the invention.

It is understood that the invention contemplates substituting straight sections of the cell structure for curved structures and *vice versa* as long as the multibonate structure of the cells is maintained.

- 15 It is also understood that the term stent, as used in this application, is directed to stents, stent-grafts, grafts and other endoluminal and intraluminal prostheses. For example, the configurations disclosed herein may be used as a framework for grafts.

- It will be also appreciated that, while the specific shapes depicted in the figures hereof contain many functional features, those functional features can all readily  
20 be obtained in other embodiments which have an overall appearance which is quite different. Therefore, the article of the figures is considered to have a novel and non-obvious ornamental appearance independent of the functional features described herein.

- While this invention may be embodied in many different forms, there are described in detail herein specific preferred embodiments of the invention. This  
25 description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated.

Those familiar with the art may recognize other equivalents to the specific embodiments described herein which equivalents are also intended to be encompassed by the claims attached hereto.

What is claimed is as follows:

1. A stent of generally cylindrical shape comprised of at least one multibonate cell structure.
2. The stent of claim 1 comprised of a plurality of interconnected multibonate cell structures.
- 5 3. The stent of claim 2 wherein the multibonate cell structures are regularly arranged.
4. The stent of claim 2 wherein all of the multibonate cell structures are tribonate, each tribonate structure having
  - 10 a common portion;
  - a first connecting portion extending from the common portion;
  - a first end portion extending from the first connecting portion;
  - a second connecting portion extending from the common portion;
  - a second end portion extending from the second connecting portion;
  - 15 a third connecting portion extending from the common portion; and
  - a third end portion extending from the third connecting portion.
5. The stent of claim 4 wherein the multibonate structures are arranged in interconnected longitudinal rows.
6. The stent of claim 5 wherein at least some of the multibonate cell structures are
  - 20 tribonate.
  7. The stent of claim 6 wherein adjacent rows of multibonate structures have connecting members extending therebetween.
  8. The stent of claim 6 wherein adjacent multibonate structures within a row are interlocking.
  - 25 9. The stent of claim 6 wherein adjacent rows of multibonate structures have connecting members extending therebetween, the connecting members being bonate cell structures.
  10. The stent of claim 9 wherein each bonate cell structure is disposed at an oblique angle relative to the longitudinal axis.
  - 30 11. The stent of claim 10 wherein the bonate cell structures are arranged in longitudinal rows,
    - all of the bonate cells within a row disposed at the same oblique angle,

bonate cell structures in adjacent rows of bonate structures oppositely disposed about a line parallel to the longitudinal axis of the stent extending between the adjacent rows of bonate structures and equidistant from the adjacent rows of bonate structures.

12. The stent of claim 6 wherein all of the multibonate structures are tribonate and 5 tribonate structures in adjacent rows of multibonate structures are rotated 180° relative to one another.

13. The stent of claim 6 wherein all of the multibonate structures are tribonate and tribonate structures in adjacent rows of multibonate structures are identically oriented relative to the longitudinal axis of the stent.

10 14. The stent of claim 6 wherein each multibonate structure is defined by a plurality of interconnected side portions and at least some of the multibonate structures have a side portion in common.

15. The stent of claim 14 wherein the multibonate structures are tribonate.

16. The stent of claim 15 wherein the multibonate structures are disposed in 15 longitudinal rows and adjacent multibonate structures in adjacent rows of multibonate structures share at least one side portion in common.

17. The stent of claim 6 wherein the tribonate structure has a threefold rotational axis of symmetry in the flat.

18. The stent of claim 6 wherein the tribonate structure has a single plane of 20 reflectional symmetry  $\sigma_v$ .

19. The stent of claim 6 wherein the second and third connecting portions are substantially the same length.

20. The stent of claim 6 wherein all three connecting portions are substantially the same length.

25 21. The stent of claim 6 where at least one of the end portions is substantially triangular in shape.

22. The stent of claim 21 wherein the substantially triangular end portion has convex sides.

23. The stent of claim 6 wherein at least two of the end portions are substantially 30 rectangular in shape.


24. The stent of claim 23 wherein the substantially rectangular end portions are formed of

a first side portion extending from the connecting portion;

- a second side portion opposite the first side portion and extending from the connecting portion; and
- an end base portion extending between the first and second side portions, wherein the base portion is substantially linear.
- 5 25. The stent of claim 23 wherein the substantially rectangular end portions are formed of
- a first side portion extending from the connecting portion;
- a second side portion opposite the first side portion and extending from the connecting portion; and
- 10 an end base portion extending between the first and second side portions, wherein the base portion is a convex curve.
26. The stent of claim 6 wherein at least some of the multibonate structures are hexabonate structures.
27. The stent of claim 26 wherein adjacent hexabonate structures have at least one 15 side in common.
28. The stent of claim 26 further comprising tribonate structures.
29. The stent of claim 28 wherein the hexabonate and tribonate structures are interlocking.
30. The stent of claim 8 comprising at least one multibonate structure of  $n^{\text{th}}$  order 20 and at least one multibonate structure of  $m^{\text{th}}$  order
- where  $n$  and  $m$  are integers greater than 2; and
- $n \neq m$ .
31. The stent of claim 6 wherein all of the multibonate cell structures are of the same tribonate cell structure.
- 25 32. The stent of claim 6 comprising interconnected quadribonate cell structures.
33. A stent comprised of at least one cell structure selected from the group consisting of bonate cell structures oriented at an oblique angle relative to the longitudinal axis of the stent, multibonate cell structures and combinations thereof.
34. The stent of claim 33 comprised of a plurality of cell structures selected from the 30 group consisting of bonate cell structures oriented at an oblique angle relative to the longitudinal axis of the stent, multibonate cell structures and combinations thereof.



35. The stent of claim 34 comprising a plurality of multibonate cell structures of different order.
36. The stent of claim 34 wherein the cell structures are interlocking.
37. A stent of generally cylindrical composed of at least one bonate cell structure  
5 disposed at an oblique angle relative to the longitudinal axis of the stent.
38. The stent of claim 37 composed of a plurality of interconnected bonate cell structures, each bonate cell structure disposed at an oblique angle relative to the longitudinal axis of the stent.
39. The stent of claim 38 consisting entirely of bonate structures.
- 10 40. The stent of claim 38 including first bonate cell structures oriented at a first oblique angle relative to the longitudinal axis of the stent and second bonate cell structures oriented at a second oblique angle relative to the longitudinal axis of the stent.
41. The stent of claim 40 wherein the first oblique and the second oblique angles are equal but oppositely disposed relative to the longitudinal axis of the stent.

*Fig. 1*




SUBSTITUTE SHEET (RULE 26)


2/27

*Fig. 2**Fig. 3*



3/27

*Fig. 4*


4/27

*Fig. 5*

5/27


**Fig. 6****Fig. 8**

*Fig. 7*




SUBSTITUTE SHEET (RULE 26)

7/27

**Fig. 9**


8/27

**Fig. 10**




9/27


Fig. 11






10/27

*Fig. 12*



11/27

*Fig. 13*

12/27


**Fig. 14a****Fig. 14b****Fig. 14c**

13/27


**Fig. 15a****Fig. 15b**

14/27


**Fig. 16a**




**Fig. 16b**



15/27

*Fig. 16c*

16/27

*Fig. 16d*

17/27




*Fig. 16e*


Fig. 17




*Fig. 18*




20/27


**Fig. 19**

21/27




22/27


***Fig. 20b***




24/27

*Fig. 21b*


25/27

**Fig. 22a**

26/27

**Fig. 22b**

27/27

**Fig. 23**

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/04686

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 697 971 A (FISCHELL ROBERT E ET AL) 16 December 1997 see figures 2,3,7	1-3
A	---	33,37,38
X	WO 96 03092 A (MEDINOL LTD ;BRUN HEIDI M (IL)) 8 February 1996 see figure 4	1-3
A	---	33,37-39
P, X	EP 0 875 215 A (SORIN BIOMEDICA CARDIO SPA) 4 November 1998 see column 5, line 35 - line 47; figures 2,3	1-3
A	-----	33,37-39

 Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art, which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the International search report

7 June 1999

14/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Neumann, E

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application

PCT/US 99/04680

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 5697971	A	16-12-1997		AU 2015497 A		29-01-1998
				CA 2204586 A		11-12-1997
				EP 0821921 A		04-02-1998
				JP 10052503 A		24-02-1998
WO 9603092	A	08-02-1996		US 5733303 A		31-03-1998
				AT 170733 T		15-09-1998
				AU 702468 B		25-02-1999
				AU 3270695 A		22-02-1996
				BR 9508353 A		04-11-1997
				CA 2195783 A		08-02-1996
				CN 1158078 A		27-08-1997
				CZ 9700191 A		11-06-1997
				DE 19581503 C		02-04-1998
				DE 19581503 T		16-01-1997
				DE 29521193 U		24-10-1996
				DE 29521205 U		19-09-1996
				DE 29521206 U		19-09-1996
				DE 69504659 D		15-10-1998
				DE 69504659 T		06-05-1999
				DK 8097 A		19-02-1997
				EP 0762856 A		19-03-1997
				EP 0846448 A		10-06-1998
				EP 0846449 A		10-06-1998
				EP 0846450 A		10-06-1998
				EP 0846451 A		10-06-1998
				EP 0846452 A		10-06-1998
				ES 2123285 T		01-01-1999
				FI 970316 A		07-03-1997
				GB 2304587 A, B		26-03-1997
				GB 2315415 A, B		04-02-1998
				JP 10503676 T		07-04-1998
				LT 97022 A, B		25-11-1997
				LU 90031 A		16-04-1997
				NO 970289 A		26-03-1997
				PL 318270 A		26-05-1997
				SE 9700206 A		28-02-1997
				SI 9520079 A		31-12-1997
				SK 11597 A		08-10-1998
				US 5843120 A		01-12-1998
EP 0875215	A	04-11-1998		IT T0970369 A		29-10-1998

**THIS PAGE BLANK (USPTO)**